PE20120249A1 - Compuestos etanaminicos - Google Patents

Compuestos etanaminicos

Info

Publication number
PE20120249A1
PE20120249A1 PE2011001282A PE2011001282A PE20120249A1 PE 20120249 A1 PE20120249 A1 PE 20120249A1 PE 2011001282 A PE2011001282 A PE 2011001282A PE 2011001282 A PE2011001282 A PE 2011001282A PE 20120249 A1 PE20120249 A1 PE 20120249A1
Authority
PE
Peru
Prior art keywords
compound
refers
pharmaceutically acceptable
acceptable salt
ethanamine
Prior art date
Application number
PE2011001282A
Other languages
English (en)
Inventor
Michael Balestra
Peter Bernstein
Glen E Ernst
William Frietze
John P Mcclauley
David Nugiel
Lihong Shen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120249(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20120249A1 publication Critical patent/PE20120249A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Confectionery (AREA)

Abstract

SE REFIERE AL COMPUESTO 2-METIL-1-FENIL-2-(PIRIDIN-2-IL)PROPAN-1-AMINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE DICHO COMPUESTO TAL COMO FUMARATO. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA DE DICHO COMPUESTO Y DE LA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO. DICHO COMPUESTO ES ANTAGONISTA DE NMDA SIENDO UTIL EN EL TRATAMIENTO DE LA DEPRESION
PE2011001282A 2008-12-24 2009-12-22 Compuestos etanaminicos PE20120249A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24

Publications (1)

Publication Number Publication Date
PE20120249A1 true PE20120249A1 (es) 2012-04-19

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001282A PE20120249A1 (es) 2008-12-24 2009-12-22 Compuestos etanaminicos

Country Status (31)

Country Link
US (4) US8013165B2 (es)
EP (2) EP2610246A1 (es)
JP (1) JP5491524B2 (es)
KR (1) KR20110097996A (es)
CN (1) CN102333762B (es)
AR (1) AR074981A1 (es)
AU (1) AU2009330745B2 (es)
BR (1) BRPI0923476A2 (es)
CA (1) CA2748235A1 (es)
CL (1) CL2011001590A1 (es)
CO (1) CO6450688A2 (es)
CR (1) CR20110365A (es)
CU (1) CU24017B1 (es)
DO (1) DOP2011000205A (es)
EA (1) EA201190064A1 (es)
EC (1) ECSP11011161A (es)
GT (1) GT201100186A (es)
HN (1) HN2011001773A (es)
IL (1) IL213518A0 (es)
MX (1) MX2011006680A (es)
NI (1) NI201100131A (es)
NZ (1) NZ593282A (es)
PE (1) PE20120249A1 (es)
SA (1) SA109310013B1 (es)
SG (2) SG171928A1 (es)
SV (1) SV2011003962A (es)
TW (1) TWI442922B (es)
UA (1) UA106056C2 (es)
UY (1) UY32360A (es)
WO (1) WO2010074647A1 (es)
ZA (1) ZA201105441B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8013165B2 (en) * 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (es) 1973-05-26 1982-11-30
US5455259A (en) 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
ES2083972T3 (es) 1988-08-12 1996-05-01 Astra Ab Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras.
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
ES2142320T3 (es) * 1991-10-30 2000-04-16 Astra Ab Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos.
UA29437C2 (uk) 1992-04-03 2000-11-15 Астра АБ (s)-альфа-феніл-2-піридинетанамін або його сіль з неорганічною кислотою, які мають протисудомну активність, спосіб їх отримання, лікарський препарат на їх основі та спосіб лікування судом
DK0898566T3 (da) * 1996-04-19 2003-03-03 Akzo Nobel Nv Substituerede benzylaminer og anvendelse deraf til behandling af depression
EP0869122B1 (en) 1997-03-31 2002-12-04 Korea Research Institute Of Chemical Technology Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) * 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
US8013165B2 (en) * 2008-12-24 2011-09-06 Astrazeneca Ab Ethanamine compounds and methods of using the same 545

Also Published As

Publication number Publication date
AR074981A1 (es) 2011-03-02
ECSP11011161A (es) 2011-07-29
CN102333762B (zh) 2014-06-11
IL213518A0 (en) 2011-07-31
WO2010074647A1 (en) 2010-07-01
US20120277272A1 (en) 2012-11-01
UY32360A (es) 2010-07-30
MX2011006680A (es) 2011-07-12
ZA201105441B (en) 2012-03-28
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
HN2011001773A (es) 2014-08-18
EP2391606A1 (en) 2011-12-07
TWI442922B (zh) 2014-07-01
EP2391606A4 (en) 2012-06-13
KR20110097996A (ko) 2011-08-31
NZ593282A (en) 2013-06-28
EP2610246A1 (en) 2013-07-03
JP5491524B2 (ja) 2014-05-14
CU20110141A7 (es) 2012-01-31
US8013165B2 (en) 2011-09-06
GT201100186A (es) 2013-10-08
EA201190064A1 (ru) 2012-02-28
CL2011001590A1 (es) 2012-06-22
JP2012513993A (ja) 2012-06-21
AU2009330745A1 (en) 2011-08-04
CN102333762A (zh) 2012-01-25
DOP2011000205A (es) 2011-07-15
US9035065B2 (en) 2015-05-19
AU2009330745B2 (en) 2012-04-05
NI201100131A (es) 2012-03-19
TW201028149A (en) 2010-08-01
CU24017B1 (es) 2014-07-30
US20130137731A1 (en) 2013-05-30
SA109310013B1 (ar) 2013-07-28
CR20110365A (es) 2011-08-09
BRPI0923476A2 (pt) 2016-01-19
CA2748235A1 (en) 2010-07-01
SV2011003962A (es) 2012-01-06
CO6450688A2 (es) 2012-05-31
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
SG171928A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
CL2013003406A1 (es) Compuestos derivados de dolastatina unidos a aminoacidos no naturales; procedimiento de preparacion; composiciones farmaceuticas, útiles en el tratamiento del cancer de mamas.
UY32062A (es) Inhibidores de beta-secretasa
CO6382125A2 (es) Inhibidores de proteína quinasa
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CL2011000558A1 (es) Formas cristalinas de un compuesto derivado de 2-tiazolil-4-quinolinil-oxi; sal de sodio del compuesto, composicion farmaceutica que comprende la sal de sodio, util para tratar una infeccion por el virus de la hepatitis c.
LT3133070T (lt) Eligliustatas (genz 112638) kaip gliukozilceramido sintazės slopiklis, skirtas naudoti fabri arba gošė ligos gydymo būde, kur būdas apima individualios terapinės dozės priderinimą paciento p-450 metabolizmui
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
PE20150204A1 (es) Inhibidores de virus de hepatitis c
PA8850801A1 (es) Compuestos útiles para inhibir chk1
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
PE20120713A1 (es) Composiciones sublinguales de dexmedetomidina y metodos para su uso
SI2176253T1 (sl) Postopek priprave ali čiščenja olmesartan medoksomila ali hidrohalidne soli olmesartan medoksomila
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.
UA113962C2 (xx) Фармацевтична композиція, яка містить апоморфін як активний інгредієнт
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
EP2432479A4 (en) OXYGEN GENERATION COMPOSITION WITH ADVANCED EFFECT FOR THE TREATMENT OF MICROBIAL INFECTIONS

Legal Events

Date Code Title Description
FC Refusal